# Novo Nordisk surged 3.5%, is the "super dose" of Wegovy coming?

Danish pharmaceutical giant Novo Nordisk has just submitted an application to the FDA to launch a **new specification of Wegovy**—a dosage of 7.2mg, which is nearly three times the highest current dosage.

**Key Highlights**:
- Impressive clinical trial data: Participants lost an average of **20.7%** (the current version is 15%)
- The FDA is using the fast track review process, and results are expected **within 1-2 months**.
- As soon as the news broke, the stock price surged, with an increase of **3.5%** today.

Interestingly, this positive news comes at just the right time. A few days ago, Novo's Alzheimer's trial failed, and its stock price took a hit. Now, the approval of the new drug specification is imminent, and the market is betting that the weight loss drug line will continue to be popular.

However, it should be noted that the market for weight loss drugs is becoming increasingly competitive. Whether Novo can maintain its leading position will depend on future clinical data and market launch progress. The recent mispricing may be real, but whether it can reverse will depend on the product's strength.